Showing results (101-110 of 349) with videos related to

Sort By:
Pageof 35
Respiratory Medicine|December 13, 2017
No genetic association detected with mepolizumab efficacy in severe asthmaLynn Condreay, Mathias Chiano, Hector Ortega, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthmaSteven W Yancey, Hector G Ortega, Oliver N Keene, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2015
Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40Jose L Gomez, Gina M Crisafi, Carole T Holm, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 16, 2012
Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroidsEugene R Bleecker, Eric D Bateman, William W Busse, et al.
American Journal of Respiratory and Critical Care Medicine|November 14, 2009
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionateEugene R Bleecker, Harold S Nelson, Monica Kraft, et al.
The Journal of Allergy and Clinical Immunology|October 18, 2003
Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populationsTimothy D Howard, Dirkje S Postma, Hajo Jongepier, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Lancet (London, England)|September 10, 2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialEugene R Bleecker, J Mark FitzGerald, Pascal Chanez, et al.
Respiratory Medicine|December 4, 2013
Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trialJan Lötvall, Eugene R Bleecker, William W Busse, et al.
Pageof 35